National, Phase II Study Designed to Evaluate the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III and IV. FAG-2
The Main objective of this study is to evaluate the faisibility of chemotherapy with
Paraplatin in combination with Taxol in patients of 70 years or older with epithelial ovary
cancer F.I.G.O. stages III and IV and to determine principal predictive factors of this
feasibility.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Feasibility of the combination Paraplatine + Taxol (at least 6 cures have been administered for a given patient and for the treated population, 50% feasibility)
Gilles Freyer, MD, PhD
Principal Investigator
Centre Hospitalier Lyon-Sud 69495 Pierre-Bénite cedex
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
FAG-2
NCT00231075
January 2001
May 2007
Name | Location |
---|